Earendil Labs, a global leader in AI-driven research and development of next-generation biologics therapeutics, and WuXi Biologics a global leading Contract Research, Development and Manufacturing Organization (CRDMO), jointly announced the signing of a strategic collaboration agreement on the development and manufacturing of multiple novel bispecific and multispecific antibodies and ADC candidates in Earendil Labs' pipeline targeting autoimmune disease, cancer, and other diseases. Under the agreement, WuXi Biologics will provide end-to-end biologics development and manufacturing services, including cell line development, process and bioassay development, drug product formulation development, and GMP manufacturing. The collaboration is designed to accelerate regulatory timelines, enhance CMC execution reliability, and support scalable global clinical development across Earendil Labs' programs. WuXi Biologics has built a strong track record in developing complex biologics, particularly its technology strengths in bispecific and multispecific antibodies and ADCs.
By 2025, a total of 945 projects were advancing on the company's integrated CRDMO platform, with bispecific and multispecific antibodies representing one of the fastest-expanding categories. Leveraging next-generation technology platforms such as the WuXia TrueSite targeted-integration CHO cell line platform and the WuXiHigh high-throughput formulation platform?together with expanded capabilities for high-dose and subcutaneous delivery, including the Hyaluronidase Co-Formulation platform and large-volume device solutions?the company provides development pathways designed to increase efficiency, strengthen product consistency, and enable seamless scale-up from early research through commercial manufacturing.
